Please login to the form below

Not currently logged in
Email:
Password:

Replagal

This page shows the latest Replagal news and features for those working in and with pharma, biotech and healthcare.

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Takeda’s Replagal (agalsidase alfa) or Sanofi Genzyme’s Fabrazyme (agalsidase beta) – for at least three years and on a stable dose administered every two weeks.

Latest news

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....